Peptide Micelle-Mediated Delivery of Tissue-Specific Suicide Gene and Combined Therapy with Avastin in a Glioblastoma Model

Journal of Pharmaceutical Sciences

Volumn 104, Issue 4, 2015, Pages 1461-1469

  Oh, Binna ^a   Han, Jaesik ^a   Choi, Eunji ^a   Tan, Xiaonan ^a   Lee, Minhyung ^a  

^a Hanyang University   (South Korea)

Author keywords

biomaterials; cancer; gene therapy; gene vectors; non viral gene delivery

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; DEOXYRIBONUCLEASE I; DNA NUCLEOTIDYLEXOTRANSFERASE; GANCICLOVIR; PEPO NI2 SV HERPES SIMPLEX VIRUS THYMIDINE KINASE; PLASMID DNA; POLYETHYLENEIMINE; R7L10 PEPTIDE; SYNTHETIC PEPTIDE; THYMIDINE KINASE; UNCLASSIFIED DRUG; ANGIOGENESIS INHIBITOR; MICELLE; PEPTIDE; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SIZE; CELL HYPOXIA; CELL VIABILITY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CYTOTOXICITY; DRUG DOSE COMPARISON; GENE EXPRESSION; GLIOBLASTOMA; IMMUNOHISTOCHEMISTRY; IN VITRO GENE TRANSFER; IN VITRO STUDY; IN VIVO STUDY; MALE; MICELLE; MOUSE; NICK END LABELING; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; RAT; SUICIDE GENE THERAPY; THERAPY EFFECT; ANIMAL; BAGG ALBINO MOUSE; BRAIN NEOPLASMS; DRUG EFFECTS; GENE THERAPY; GENETIC TRANSFECTION; GENETICS; METABOLISM; MULTIMODALITY CANCER THERAPY; NUDE MOUSE; PATHOLOGY; PROCEDURES; SUICIDE TRANSGENE; TIME; TUMOR CELL LINE; TUMOR VOLUME; VASCULARIZATION; XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; BEVACIZUMAB; BRAIN NEOPLASMS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; GENES, TRANSGENIC, SUICIDE; GENETIC THERAPY; GLIOBLASTOMA; HETEROGRAFTS; MALE; MICE, INBRED BALB C; MICE, NUDE; MICELLES; PEPTIDES; RATS; THYMIDINE KINASE; TIME FACTORS; TRANSFECTION; TUMOR BURDEN; VIRAL PROTEINS;

EID: 84924800887     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.24363     Document Type: Article

References (38)

1. Karpati G, Li H, Nalbantoglu J. 1999. Molecular therapy for glioblastoma. Curr Opin Mol Therap 1(5):545-552.
2. Alemany R, Gomez-Manzano C, Balague C, Yung WK, Curiel DT, Kyritsis AP, Fueyo J. 1999. Gene therapy for gliomas: Molecular targets, adenoviral vectors, and oncolytic adenoviruses. Exp Cell Res 252(1):1-12.
3. Altaner C. 2008. Prodrug cancer gene therapy. Cancer Lett 270(2):191-201.
4. Castro MG, Candolfi M, Kroeger K, King GD, Curtin JF, Yagiz K, Mineharu Y, Assi H, Wibowo M, Ghulam Muhammad AK, Foulad D, Puntel M, Lowenstein PR. 2011. Gene therapy and targeted toxins for glioma. Curr Gene Ther 11(3):155-180.
5. Ghulam Muhammad AK, Candolfi M, King GD, Yagiz K, Foulad D, Mineharu Y, Kroeger KM, Treuer KA, Nichols WS, Sanderson NS, Yang J, Khayznikov M, VanRooijen N, Lowenstein PR, Castro MG. 2009. Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: Humoral and cellular immunity lead to tumor regression. Clin Cancer Res 15(19):6113-6127.
6. Muhammad AK, Puntel M, Candolfi M, Salem A, Yagiz K, Farrokhi C, Kroeger KM, Xiong W, Curtin JF, Liu C, Lawrence K, Bondale NS, Lerner J, Baker GJ, Foulad D, Pechnick RN, Palmer D, Ng P, Lowenstein PR, Castro MG. 2010. Study of the efficacy, biodistribution, and safety profile of therapeutic gutless adenovirus vectors as a prelude to a phase I clinical trial for glioblastoma. Clin Pharmacol Ther 88(2):204-213.
7. Voges J, Reszka R, Gossmann A, Dittmar C, Richter R, Garlip G, Kracht L, Coenen HH, Sturm V, Wienhard K, Heiss WD, Jacobs AH. 2003. Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma. Ann Neurol 54(4):479-487.
8. Kim HA, Park JH, Yi N, Lee M. 2014. Delivery of hypoxia and glioma dual-specific suicide gene using dexamethasone conjugated polyethylenimine for glioblastoma-specific gene therapy. Mol Pharm 11(3):938-950.
9. Kang HC, Lee M, Bae YH. 2005. Polymeric gene carriers. Crit Rev Eukaryot Gene Expr 15(4):317-342.
10. Benns JM, Maheshwari A, FurgesonDY, Mahato RI, Kim SW. 2001. Folate-PEG-folate-graft-polyethylenimine-based gene delivery. J Drug Target 9(2):123-139.
11. Lee M, Rentz J, Han SO, Bull DA, Kim SW. 2003. Water-soluble lipopolymer as an efficient carrier for gene delivery to myocardium. Gene Ther 10(7):585-593.
12. Park JH, Kim HA, Park JH, Lee M. 2012. Amphiphilic peptide carrier for the combined delivery of curcumin and plasmid DNA into the lungs. Biomaterials 33(27):6542-6550.
13. Ryu DW, Kim HA, Song H, Kim S, Lee M. 2011. Amphiphilic peptides with arginines and valines for the delivery of plasmid DNA. J Cell Biochem 112(5):1458-1466.
14. Yi N, Oh B, Kim HA, Lee M. 2014. Combined delivery of BCNU and VEGF siRNA using amphiphilic peptides for glioblastoma. J Drug Target 22(2):156-164.
15. Park JH, Kim HA, Cho SH, Lee M. 2012. Characterization of hydrophobic anti-cancer drug-loaded amphiphilic peptides as a gene carrier. J Cell Biochem 113(5):1645-1653.
16. Hsu JY, Wakelee HA. 2009. Monoclonal antibodies targeting vascular endothelial growth factor: Current status and future challenges in cancer therapy. BioDrugs 23(5):289-304.
17. Specenier P. 2012. Bevacizumab in glioblastoma multiforme. Expert Rev Anticancer Ther 12(1):9-18.
18. Lee M, Rentz J, Bikram M, Han S, Bull DA, Kim SW. 2003. Hypoxia-inducible VEGF gene delivery to ischemic myocardium using water-soluble lipopolymer. Gene Ther 10(18):1535-1542.
19. Choi UH, Ha Y, Huang X, Park SR, Chung J, Hyun DK, Park H, Park HC, Kim SW, Lee M. 2007. Hypoxia-inducible expression of vascular endothelial growth factor for the treatment of spinal cord injury in a rat model. J Neurosurg Spine 7(1):54-60.
20. Lee M, Lee ES, Kim YS, Choi BH, Park SR, Park HS, Park HC, Kim SW, Ha Y. 2005. Ischemic injury-specific gene expression in the rat spinal cord injury model using hypoxia-inducible system. Spine 30(24):2729-2734.
21. Lendahl U, Zimmerman LB, McKay RD. 1990. CNS stem cells express a new class of intermediate filament protein. Cell 60(4):585-595.
22. Lothian C, Lendahl U. 1997. An evolutionarily conserved region in the second intron of the human nestin gene directs gene expression to CNS progenitor cells and to early neural crest cells. Eur J Neurosci 9(3):452-462.
23. Zimmerman L, Parr B, Lendahl U, Cunningham M, McKay R, Gavin B, Mann J, Vassileva G, McMahon A. 1994. Independent regulatory elements in the nestin gene direct transgene expression to neural stem cells or muscle precursors. Neuron 12(1):11-24.
24. Lemkine GF, Goula D, Becker N, Paleari L, Levi G, Demeneix BA. 1999. Optimisation of polyethylenimine-based gene delivery to mouse brain. J Drug Target 7(4):305-312.
25. Turunen MP, Hiltunen MO, Ruponen M, Virkamaki L, Szoka FC, Jr, Urtti A, Yla-Herttuala S. 1999. Efficient adventitial gene delivery to rabbit carotid artery with cationic polymer-plasmid complexes. Gene Ther 6(1):6-11.
26. Pizzato M, Franchin E, Calvi P, Boschetto R, Colombo M, Ferrini S, Palu G. 1998. Production and characterization of a bicistronic Moloney-based retroviral vector expressing human interleukin 2 and herpes simplex virus thymidine kinase for gene therapy of cancer. Gene Ther 5(7):1003-1007.
27. Klatzmann D, Valery CA, Bensimon G, Marro B, Boyer O, Mokhtari K, Diquet B, Salzmann JL, Philippon J. 1998. A phase I/II study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for recurrent glioblastoma. Study group on gene therapy for glioblastoma. Hum Gene Ther 9(17):2595-2604.
28. Su H, Lu R, Chang JC, Kan YW. 1997. Tissue-specific expression of herpes simplex virus thymidine kinase gene delivered by adeno-associated virus inhibits the growth of human hepatocellular carcinoma in athymic mice. Proc Natl Acad Sci USA 94(25):13891-13896.
29. Adachi Y, Reynolds PN, Yamamoto M, Grizzle WE, Overturf K, Matsubara S, Muramatsu T, Curiel DT. 2000. Midkine promoter-based adenoviral vector gene delivery for pediatric solid tumors. Cancer Res 60(16):4305-4310.
30. Cao G, Kuriyama S, Gao J, Nakatani T, Chen Q, Yoshiji H, Zhao L, Kojima H, Dong Y, Fukui H, Hou J. 2001. Gene therapy for hepatocellular carcinoma based on tumour-selective suicide gene expression using the alpha-fetoprotein (AFP) enhancer and a housekeeping gene promoter. Eur J Cancer 37(1):140-147.
31. Qiao J, Doubrovin M, Sauter BV, Huang Y, Guo ZS, Balatoni J, Akhurst T, Blasberg RG, Tjuvajev JG, Chen SH,Woo SL. 2002. Tumor-specific transcriptional targeting of suicide gene therapy. Gene Ther 9(3):168-175.
32. Kim HA, Nam K, Lee M, Kim SW. 2013. Hypoxia/hepatoma dual specific suicide gene expression plasmid delivery using bio-reducible polymer for hepatocellular carcinoma therapy. J Control Release 171(1):1-10.
33. Park JH, Han J, Lee M. 2014. Thymidine kinase gene delivery using curcumin loaded peptide micelles as a combination therapy for glioblastoma. Pharm Res.[Epub ahead of print]
34. Yin W, Cao G, Johnnides MJ, Signore AP, Luo Y, Hickey RW, Chen J. 2006. TAT-mediated delivery of Bcl-xL protein is neuroprotective against neonatal hypoxic-ischemic brain injury via inhibition of caspases and AIF. Neurobiol Dis 21(2):358-371.
35. Kilic E, Dietz GP, Hermann DM, Bahr M. 2002. Intravenous TAT-Bcl-Xl is protective after middle cerebral artery occlusion in mice. Ann Neurol 52(5):617-622.
36. Wen X, Wang K, Zhao Z, Zhang Y, Sun T, Zhang F, Wu J, Fu Y, Du Y, Zhang L, Sun Y, Liu Y, Ma K, Liu H, Song Y. 2014. Brain-targeted delivery of trans-activating transcriptor-conjugated magnetic PLGA/lipid nanoparticles. PLoS One 9(9):e106652.
37. Kuang Y, An S, Guo Y, Huang S, Shao K, Liu Y, Li J, Ma H, Jiang C. 2013. T7 peptide-functionalized nanoparticles utilizing RNA interference for glioma dual targeting. Int J Pharm 454(1):11-20.
38. Kim ID, Shin JH, Kim SW, Choi S, Ahn J, Han PL, Park JS, Lee JK. 2012. Intranasal delivery of HMGB1 siRNA confers target gene knockdown and robust neuroprotection in the postischemic brain. Mol Ther 20(4):829-839.